NCT07337096
Electro-Acupuncture in Lung cancER : EALER Study
Recruiting · Not Applicable · Guangzhou University of Traditional Chinese Medicine · registry updated 2026-06-24
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This multicentre, randomized controlled trial evaluates the effect and safety of acupuncture combing with PD-1 inhibitors plus chemotherapy in NSCLC. Participants will be randomly assigned to undergo either acupuncture or sham acupuncture concurrent with the initial four-six cycles of chemotherapy combined with PD-1 inhibitors.
Inclusion
- Pathologically confirmed NSCLC, with AJCC lung cancer TNM stage IV.
- Tumor proportion score for PD-L1 \< 50%.
- Lacks targetable gene mutations (including but not limited to EGFR mutations or ALK fusions).
- No prior systemic therapy for advanced NSCLC (including chemotherapy, targeted therapy, or immunotherapy). Patients planned to receive first-line (induction) treatment with ICIs plus chemotherapy are eligible. Patients who have received prior neoadjuvant or adjuvant therapy, or definitive chemoradiotherapy, may be enrolled if provided that disease progression occurred more than 6 months after the completion of the last treatment.
- ECOG performance status score of 0-2.
- Age ≥ 18 years.
Exclusion
- Inability to complete baseline assessments.
- Pregnant or lactating women, and those with psychiatric, intellectual, or language disorders.
- Patients with autoimmune diseases or hematologic disorders requiring long-term use of hormones or immunosuppressants.
- Presence of concurrent primary malignant tumors at other sites.
- Participation in another investigational drug or device clinical trial within 30 days prior to the planned initiation of study treatment.
- Known seropositivity for human immunodeficiency virus (HIV), other congenital or acquired immunodeficiencies, or history of organ or stem cell transplantation (including autologous bone marrow or peripheral blood stem cell transplantation).